{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T11:00:50Z","timestamp":1648897250636},"reference-count":15,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,3,1]]},"abstract":"<jats:p>Testolactone, an aromatase inhibitor, blocks conversion of androgens to estrogens. In familial male precocious puberty, slowing of pubertal progression and growth velocity occurs with testolactone and spironolactone. Girls with McCune-Albright syndrome, given testolactone, respond similarly. A 2-yr-old female (case 1) on testolactone for non-McCune-Albright gonadotropin independent precocious puberty had marked elevations of androstenedione (18 ng\/mL, normal: 0.2\u20133.1) and testosterone (3.6 ng\/mL, normal &amp;lt; 0.2) but no virilization. Investigations were undertaken to determine whether elevations in testosterone and androstenedione were caused by interference in these RIAs. After a single oral dose of testolactone (5 mg\/kg in case 1; 4 mg\/kg in case 2, a 3-yr-old boy with familial male precocious puberty; 10 mg\/kg in a healthy postmenopausal control), serum testosterone and androstenedione were measured serially by RIA for 24 h. Androstenedione went from normal to a mean peak of 45.4 ng\/mL at 1\u20132 h and returned to baseline by 24 h. Testosterone, undetectable at baseline (case 1 and control) or 1.8 ng\/mL (case 2) rose to a mean peak of 6.9 ng\/mL and returned to baseline by 24 h. Testolactone, in serial dilutions, cross-reacted in the testosterone assay. Testolactone significantly interferes in these serum RIAs, making their use unreliable in follow-up of patients treated with testolactone.<\/jats:p>","DOI":"10.1210\/jcem.83.3.4623","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:02:57Z","timestamp":1389200577000},"page":"784-787","source":"Crossref","is-referenced-by-count":0,"title":["Testolactone-Associated High Androgen Levels, a Pharmacologic Effect or a Laboratory Artifact?1"],"prefix":"10.1210","volume":"83","author":[{"given":"Elizabeth A.","family":"Cummings","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology, IWK Grace Health Centre (E.A.C., S.R.S.), Nova Scotia, Canada B3J 3G9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia R.","family":"Salisbury","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology, IWK Grace Health Centre (E.A.C., S.R.S.), Nova Scotia, Canada B3J 3G9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morris L.","family":"Givner","sequence":"additional","affiliation":[{"name":"Department of Pathology (M.L.G.), Nova Scotia, Canada B3J 3G9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger S.","family":"Rittmaster","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology (R.S.R.). Dalhousie University, Halifax, Nova Scotia, Canada B3J 3G9"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071619400927000_R1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1530\/acta.0.1090254","article-title":"Testolactone treatment of precocious puberty in McCune-Albright syndrome.","volume":"109","author":"Foster","year":"1985","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071619400927000_R2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJM198610303151802","article-title":"Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.","volume":"315","author":"Feuillan","year":"1986","journal-title":"N Engl J Med"},{"key":"2020071619400927000_R3","first-page":"647","article-title":"Long term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.","volume":"77","author":"Feuillan","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619400927000_R4","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1210\/jcem-73-6-1370","article-title":"Luteinizing hormone-releasing hormone independent precocious puberty unresponsive to LHRH agonist therapy in two girls lacking features of the McCune-Albright syndrome.","volume":"73","author":"Feuillan","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619400927000_R5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM198902233200805","article-title":"Treatment of familial male precocious puberty with spironolactone and testolactone.","volume":"320","author":"Laue","year":"1989","journal-title":"N Engl J Med"},{"key":"2020071619400927000_R6","first-page":"151","article-title":"Treatment of familial male precocious puberty with spironolactone, testolactone and deslorelin.","volume":"76","author":"Laue","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619400927000_R7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00682741","article-title":"First generation aromatase inhibitors - aminoglutethimide and testolactone.","volume":"30","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"2020071619400927000_R8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1210\/endo-110-1-214","article-title":"The antiandrogenic effects of \u03941-testolactone(teslac) in vivo in rats and in vitro in human cultured fibroblasts, rat mammary carcinoma cells and rat prostate cytosol.","volume":"110","author":"Vigersky","year":"1982","journal-title":"Endocrinology"},{"key":"2020071619400927000_R9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1210\/jcem-59-1-51","article-title":"The use of human skin fibrobasts to obtain potency estimates of drug binding to androgen receptors.","volume":"59","author":"Eil","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619400927000_R10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/1097-0142(196205\/06)15:3<633::AID-CNCR2820150327>3.0.CO;2-L","article-title":"Hormonal therapy in cancer of the breast XIX. Effect of oral administration of \u03941-testololactone on clinical course and hormonal excretion.","volume":"15","author":"Segaloff","year":"1962","journal-title":"Cancer"},{"key":"2020071619400927000_R11","first-page":"218","volume":"279","author":"Zachmann","year":"1986"},{"key":"2020071619400927000_R12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1210\/jcem-52-5-897","article-title":"Effects of\u0394 1-testolactone on the pituitary-testicular axis in oligospermic men.","volume":"52","author":"Vigersky","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619400927000_R13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1210\/jcem-60-4-773","article-title":"The effects of the aromatase inhibitor \u03941-testolactone on gonadotropin release and steroid metabolism in polycystic ovarian disease.","volume":"60","author":"Dunaif","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619400927000_R14","first-page":"3345","volume":"42","author":"Judd","year":"1982"},{"key":"2020071619400927000_R15","first-page":"3535","article-title":"A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.","volume":"81","author":"Laue","year":"1996","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/83\/3\/784\/9228985\/jcem0784.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/83\/3\/784\/9228985\/jcem0784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T04:41:14Z","timestamp":1594960874000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/83\/3\/784\/2865174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3,1]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.83.3.4623","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,3,1]]}}}